# What would establish the identity of both compounds in a mixture?

- Article ID: research-079
- Product: CJC-1295 (No DAC) / GHRP-2 (cjc-1295-ghrp-2-674)
- Canonical page: https://heritagebiolabs.com/research-library/articles/079-what-would-establish-the-identity-of-both-compounds-in-a-mixture
- Product collection: https://heritagebiolabs.com/research-library/products/cjc-1295-no-dac-ghrp-2
- Product page: https://heritagebiolabs.com/product/cjc-1295-ghrp-2-674
- Reading focus: Methods & identity (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2010, 2024, 2025

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Short chains of amino acids joined by peptide bonds can have similar names and different biological actions. CJC-1295 (No DAC) / GHRP-2 combines a name commonly used for the modified 29-residue growth hormone–releasing factor with pralmorelin, a six-residue peptide. A chemical identification of this exact pairing would have to account for both chains. [1, 2]

A 2010 Norwegian laboratory report offers an older example of identifying the no-DAC component. The investigators separated components of an unknown preparation and used high-resolution mass spectrometry to measure an intact peptide and smaller pieces of it. They proposed a sequence for a 29-residue peptide. The FDA later noted that its reported formula and mass were consistent with the no-DAC form, without establishing the salt form of the original material. [1, 3]

That paper studied one unknown sample, with no claim to have identified the two-peptide combination. In a mixture, researchers would need independent evidence for each chain. A measurement can be specific enough to distinguish a peptide from an unrelated compound yet insufficient to distinguish it from a closely related sequence. Looking at characteristic fragments can help make the assignment more specific. Identity, quantity and purity also answer different questions, even when all refer to the same preparation. [1, 3]

No recent primary analytical study of the exact GHRP-2 mixture was identified. The example shows the scope of a single-compound identification. The regulatory record for Japan's pralmorelin product establishes an identity for that approved diagnostic ingredient, and the Norwegian report supports a different identity in its own sample. Neither document characterizes the contents or stability of this catalog pairing. [1, 2, 3]

## Sources

1. U.S. Food and Drug Administration. December 4, 2024 Pharmacy Compounding Advisory Committee (PCAC) Meeting. FDA briefing document on CJC-1295-related bulk drug substances (publication 2024-12-04). <https://www.fda.gov/media/183819/download>
2. Japan Pharmaceuticals and Medical Devices Agency. 注射用GHRP科研100. PMDA package insert (publication 2025-07). <https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/200022_7223407D2023_1_01>
3. Henninge J et al. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Testing and Analysis (publication 2010-12-10). <https://pubmed.ncbi.nlm.nih.gov/21204297/>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 016 - CJC-1295 (No DAC) GHRP-2 and CJC-1295 (No DAC) GHRP-6.docx; article 79; content SHA-256 d4ca803499e6413d47e2b47b9fa026b31ee9e8e81463ff6546476cc8dbf6894e.
